Episode Details

In this STtalks we learn about the critical contributions made by Cytonome®-ST to achieve a major milestone in regenerative medicine by getting the approval for an iPSC-derived Parkinson’s cell therapy developed by Sumitomo Pharma and RACK-THERA in Japan. John Sharpe, Cytonome®-ST COO, explains Cytonome®-ST’s biotechnology engineering focus on measuring and isolating cells, its evolution from Genesis platforms, and how global reliability is maintained through consistency and quality control, along with connected monitoring systems. He emphasizes the importance of single-cell selection, high-throughput performance, and why precise selection is critical in regenerative medicine because “the cells are the drug.”